NAMS MENOPAUSE CERTIFICATION EXAM BANK |
MENOPAUSE SOCIETY CERTIFIED PRACTITIONER
(MSCP) EXAM | REAL EXAM CURRENTLY TESTING |
EXPERT VERIFIED FOR GUARANTEED PASS 2026
MSCP Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest NAMS Guidelines | Graded A+
This comprehensive exam bank contains 250 expert-verified questions designed to prepare candidates
for the Menopause Society Certified Practitioner (MSCP) certification exam. Each question reflects the
current testing blueprint and clinical practice guidelines from the North American Menopause Society
(NAMS). Detailed rationales and distractor explanations reinforce key concepts in menopause
management. Ideal for clinicians seeking a guaranteed pass on the 2026/2027 exam cycle.
Key Features:
Menopause physiology and endocrinology
Hormone therapy: indications, risks, and benefits
Non-hormonal management of vasomotor symptoms
Genitourinary syndrome of menopause (GSM)
Bone health and osteoporosis prevention
Cardiovascular and cognitive health in menopause
Updates for 2026:
- Updated to reflect 2026 NAMS position statements
- Incorporated new FDA-approved non-hormonal therapies
- Revised cardiovascular risk assessment algorithms
- Added questions on telehealth and patient counseling
- Expanded coverage of breast cancer risk and HT
Abstract:
The Menopause Society Certified Practitioner (MSCP) exam is a rigorous assessment of clinical competence in
menopause management. This 250-question bank is meticulously curated to mirror the current exam content,
covering physiology, hormone therapy, non-hormonal treatments, genitourinary syndrome, bone health, and
cardiovascular risk. Each question includes a detailed rationale explaining the correct answer and why distractors
are incorrect, based on the latest NAMS guidelines. The document is designed for active recall and spaced
repetition, ensuring deep retention. Expert verification guarantees alignment with 2026/2027 exam standards. This
resource is essential for clinicians aiming for certification and excellence in menopause care.
Keywords:
MSCP exam, NAMS certification, menopause management, hormone therapy, vasomotor symptoms, genitourinary
syndrome, osteoporosis, 2026 guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying
physiology or clinical evidence. Distractor options are analyzed to clarify common misconceptions and reinforce
correct clinical reasoning.
Compliance Checklist:
Aligned with 2026 NAMS clinical practice guidelines
Covers all domains of the MSCP exam blueprint
Page 1
, Each question verified by subject matter experts
Includes rationales for both correct and incorrect answers
Designed for self-assessment and mastery learning
Content Area Overview:
Content Area Questions Key Topics Weight
Menopause Physiology and 1-40 hypothalamic-pituitary-ovarian axis, 16%
Endocrinology perimenopause, postmenopause, hormonal
changes
Hormone Therapy 41-100 estrogen therapy, progestogen therapy, 24%
compounded vs. FDA-approved, risks and
benefits
Non-Hormonal Management of 101-140 SSRIs/SNRIs, gabapentin, clonidine, 16%
Vasomotor Symptoms lifestyle modifications, alternative therapies
Genitourinary Syndrome of 141-170 vaginal atrophy, dyspareunia, urinary 12%
Menopause (GSM) symptoms, local estrogen therapy,
moisturizers
Bone Health and Osteoporosis 171-210 bone density testing, calcium/vitamin D, 16%
bisphosphonates, denosumab, teriparatide
Cardiovascular and Cognitive 211-250 heart disease risk, lipid changes, cognitive 16%
Health decline, timing hypothesis, lifestyle
interventions
Page 2
,Q1. A 52-year-old woman with a history of estrogen receptor-positive breast cancer 5 years ago presents with
severe hot flashes and night sweats that disrupt sleep. She has tried lifestyle modifications and
over-the-counter supplements without relief. Which of the following is the most appropriate next step in
management according to current NAMS guidelines?
A. Initiate low-dose oral estradiol with a progestin for endometrial protection
B. Prescribe paroxetine 7.5 mg once daily
C. Recommend vaginal conjugated equine estrogen cream
D. Refer for cognitive behavioral therapy (CBT) as first-line treatment
Correct Answer: B. Prescribe paroxetine 7.5 mg once daily
Rationale: For women with a history of estrogen-sensitive breast cancer, systemic hormone therapy is
contraindicated. Paroxetine is a non-hormonal SSRI that is FDA-approved for moderate-to-severe vasomotor
symptoms and is considered first-line pharmacotherapy in this setting. Vaginal estrogen is low-dose and may be
considered for genitourinary symptoms, but it does not address systemic vasomotor symptoms. CBT is effective but
is not pharmacotherapy and may not be sufficient as monotherapy for severe symptoms.
Why Wrong:
A - Systemic estrogen is contraindicated in estrogen receptor-positive breast cancer survivors due to risk of
recurrence.
C - Vaginal estrogen is minimally absorbed and not effective for systemic vasomotor symptoms.
D - CBT is a non-pharmacologic option but is not the most appropriate next step for severe symptoms after
lifestyle modifications fail; pharmacotherapy is indicated.
Reference: NAMS 2022 Hormone Therapy Position Statement; Menopause 2022;29(7):767-794.
Q2. A 60-year-old woman with a body mass index (BMI) of 32 kg/m² and no prior history of
thromboembolism is considering systemic hormone therapy for bothersome vasomotor symptoms. She has an
intact uterus. Which of the following statements regarding the risk of venous thromboembolism (VTE) with
different hormone therapy regimens is most accurate?
A. Transdermal estradiol with micronized progesterone carries a lower VTE risk than oral conjugated equine
estrogen with medroxyprogesterone acetate.
B. Oral estradiol with a levonorgestrel intrauterine device has a higher VTE risk than oral conjugated equine
estrogen alone.
C. All routes of estrogen administration have similar VTE risk in women with obesity.
D. The addition of a progestogen to estrogen therapy reduces VTE risk.
Correct Answer: A. Transdermal estradiol with micronized progesterone carries a lower VTE risk than oral
conjugated equine estrogen with medroxyprogesterone acetate.
Rationale: Transdermal estradiol avoids first-pass hepatic metabolism and is associated with a lower risk of VTE
compared to oral estrogen. Micronized progesterone has a more favorable metabolic profile than
medroxyprogesterone acetate. The levonorgestrel IUD is a progestin-only device and does not increase VTE risk;
oral estrogen alone (without progestin) would increase VTE risk. Obesity is an independent risk factor for VTE, but
transdermal route still confers lower risk. Progestogens do not reduce VTE risk; some may increase it.
Why Wrong:
B - Oral estradiol with a levonorgestrel IUD has lower VTE risk than oral conjugated equine estrogen alone
because the IUD provides local progestin without systemic effects.
C - Transdermal estrogen has lower VTE risk than oral, even in obese women.
D - Progestogens do not reduce VTE risk; some studies suggest an increased risk with certain progestins.
Reference: Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women.
Climacteric. 2020;23(sup1):S3-S8.
Page 3
, Q3. A 45-year-old woman with premature ovarian insufficiency (POI) diagnosed at age 40 has been on
transdermal estradiol 50 mcg/day with cyclic micronized progesterone 200 mg for 12 days per month. She is
now considering pregnancy. Which of the following is the most appropriate management strategy regarding
her hormone therapy?
A. Continue current hormone therapy until pregnancy is confirmed, then discontinue.
B. Switch to a continuous-combined regimen to suppress ovulation.
C. Discontinue hormone therapy and use donor oocyte in vitro fertilization (IVF) with exogenous estrogen support.
D. Increase estradiol dose to 100 mcg/day to improve endometrial receptivity.
Correct Answer: C. Discontinue hormone therapy and use donor oocyte in vitro fertilization (IVF) with exogenous
estrogen support.
Rationale: In POI, spontaneous pregnancy is rare, and most women require donor oocytes. Exogenous estrogen is needed for
endometrial preparation in IVF cycles. Current hormone therapy should be discontinued to allow controlled ovarian
stimulation or endometrial preparation. Continuous-combined therapy does not suppress ovulation sufficiently for IVF.
Increasing estradiol dose without monitoring is not recommended.
Why Wrong:
A - Hormone therapy provides only replacement levels of estrogen and does not support pregnancy; it should be replaced
by controlled IVF protocols.
B - Continuous-combined therapy is used for contraception in POI but is not appropriate for pregnancy planning.
D - Higher estrogen doses are not indicated without monitoring and may increase risks; standard IVF protocols use
monitored estrogen.
Reference: Webber L, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod.
2016;31(5):926-937.
Q4. A 58-year-old woman with a history of osteoporosis (T-score -2.8 at lumbar spine) and prior vertebral
fracture is intolerant to bisphosphonates due to severe gastrointestinal side effects. She has completed 5 years
of denosumab therapy. Which of the following is the most appropriate next step to prevent fracture?
A. Continue denosumab indefinitely without a drug holiday.
B. Transition to teriparatide for 2 years.
C. Start raloxifene therapy.
D. Administer a single dose of zoledronic acid and then observe.
Correct Answer: B. Transition to teriparatide for 2 years.
Rationale: After denosumab discontinuation, there is a high risk of rapid bone loss and rebound fractures.
Transitioning to teriparatide, an anabolic agent, can increase bone density and reduce fracture risk. Denosumab
should not be continued indefinitely beyond 5 years without reassessment, but stopping without follow-on therapy is
dangerous. Raloxifene is less potent and not first-line for severe osteoporosis with fracture. Zoledronic acid can be
used after denosumab to prevent rebound, but teriparatide provides anabolic benefit and is appropriate given prior
bisphosphonate intolerance and severe disease.
Why Wrong:
A - Denosumab beyond 5 years requires reassessment; continuing without transition increases risk of atypical
femur fractures and osteonecrosis of the jaw.
C - Raloxifene is a SERM with modest anti-fracture efficacy and is not indicated for severe osteoporosis with
prior fracture.
D - Zoledronic acid may prevent bone loss after denosumab but does not provide the anabolic effect needed
for this patient with severe osteoporosis and fracture.
Reference: Tsourdi E, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and
position statement by ECTS. Bone. 2017;105:11-17.
Page 4
MENOPAUSE SOCIETY CERTIFIED PRACTITIONER
(MSCP) EXAM | REAL EXAM CURRENTLY TESTING |
EXPERT VERIFIED FOR GUARANTEED PASS 2026
MSCP Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest NAMS Guidelines | Graded A+
This comprehensive exam bank contains 250 expert-verified questions designed to prepare candidates
for the Menopause Society Certified Practitioner (MSCP) certification exam. Each question reflects the
current testing blueprint and clinical practice guidelines from the North American Menopause Society
(NAMS). Detailed rationales and distractor explanations reinforce key concepts in menopause
management. Ideal for clinicians seeking a guaranteed pass on the 2026/2027 exam cycle.
Key Features:
Menopause physiology and endocrinology
Hormone therapy: indications, risks, and benefits
Non-hormonal management of vasomotor symptoms
Genitourinary syndrome of menopause (GSM)
Bone health and osteoporosis prevention
Cardiovascular and cognitive health in menopause
Updates for 2026:
- Updated to reflect 2026 NAMS position statements
- Incorporated new FDA-approved non-hormonal therapies
- Revised cardiovascular risk assessment algorithms
- Added questions on telehealth and patient counseling
- Expanded coverage of breast cancer risk and HT
Abstract:
The Menopause Society Certified Practitioner (MSCP) exam is a rigorous assessment of clinical competence in
menopause management. This 250-question bank is meticulously curated to mirror the current exam content,
covering physiology, hormone therapy, non-hormonal treatments, genitourinary syndrome, bone health, and
cardiovascular risk. Each question includes a detailed rationale explaining the correct answer and why distractors
are incorrect, based on the latest NAMS guidelines. The document is designed for active recall and spaced
repetition, ensuring deep retention. Expert verification guarantees alignment with 2026/2027 exam standards. This
resource is essential for clinicians aiming for certification and excellence in menopause care.
Keywords:
MSCP exam, NAMS certification, menopause management, hormone therapy, vasomotor symptoms, genitourinary
syndrome, osteoporosis, 2026 guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying
physiology or clinical evidence. Distractor options are analyzed to clarify common misconceptions and reinforce
correct clinical reasoning.
Compliance Checklist:
Aligned with 2026 NAMS clinical practice guidelines
Covers all domains of the MSCP exam blueprint
Page 1
, Each question verified by subject matter experts
Includes rationales for both correct and incorrect answers
Designed for self-assessment and mastery learning
Content Area Overview:
Content Area Questions Key Topics Weight
Menopause Physiology and 1-40 hypothalamic-pituitary-ovarian axis, 16%
Endocrinology perimenopause, postmenopause, hormonal
changes
Hormone Therapy 41-100 estrogen therapy, progestogen therapy, 24%
compounded vs. FDA-approved, risks and
benefits
Non-Hormonal Management of 101-140 SSRIs/SNRIs, gabapentin, clonidine, 16%
Vasomotor Symptoms lifestyle modifications, alternative therapies
Genitourinary Syndrome of 141-170 vaginal atrophy, dyspareunia, urinary 12%
Menopause (GSM) symptoms, local estrogen therapy,
moisturizers
Bone Health and Osteoporosis 171-210 bone density testing, calcium/vitamin D, 16%
bisphosphonates, denosumab, teriparatide
Cardiovascular and Cognitive 211-250 heart disease risk, lipid changes, cognitive 16%
Health decline, timing hypothesis, lifestyle
interventions
Page 2
,Q1. A 52-year-old woman with a history of estrogen receptor-positive breast cancer 5 years ago presents with
severe hot flashes and night sweats that disrupt sleep. She has tried lifestyle modifications and
over-the-counter supplements without relief. Which of the following is the most appropriate next step in
management according to current NAMS guidelines?
A. Initiate low-dose oral estradiol with a progestin for endometrial protection
B. Prescribe paroxetine 7.5 mg once daily
C. Recommend vaginal conjugated equine estrogen cream
D. Refer for cognitive behavioral therapy (CBT) as first-line treatment
Correct Answer: B. Prescribe paroxetine 7.5 mg once daily
Rationale: For women with a history of estrogen-sensitive breast cancer, systemic hormone therapy is
contraindicated. Paroxetine is a non-hormonal SSRI that is FDA-approved for moderate-to-severe vasomotor
symptoms and is considered first-line pharmacotherapy in this setting. Vaginal estrogen is low-dose and may be
considered for genitourinary symptoms, but it does not address systemic vasomotor symptoms. CBT is effective but
is not pharmacotherapy and may not be sufficient as monotherapy for severe symptoms.
Why Wrong:
A - Systemic estrogen is contraindicated in estrogen receptor-positive breast cancer survivors due to risk of
recurrence.
C - Vaginal estrogen is minimally absorbed and not effective for systemic vasomotor symptoms.
D - CBT is a non-pharmacologic option but is not the most appropriate next step for severe symptoms after
lifestyle modifications fail; pharmacotherapy is indicated.
Reference: NAMS 2022 Hormone Therapy Position Statement; Menopause 2022;29(7):767-794.
Q2. A 60-year-old woman with a body mass index (BMI) of 32 kg/m² and no prior history of
thromboembolism is considering systemic hormone therapy for bothersome vasomotor symptoms. She has an
intact uterus. Which of the following statements regarding the risk of venous thromboembolism (VTE) with
different hormone therapy regimens is most accurate?
A. Transdermal estradiol with micronized progesterone carries a lower VTE risk than oral conjugated equine
estrogen with medroxyprogesterone acetate.
B. Oral estradiol with a levonorgestrel intrauterine device has a higher VTE risk than oral conjugated equine
estrogen alone.
C. All routes of estrogen administration have similar VTE risk in women with obesity.
D. The addition of a progestogen to estrogen therapy reduces VTE risk.
Correct Answer: A. Transdermal estradiol with micronized progesterone carries a lower VTE risk than oral
conjugated equine estrogen with medroxyprogesterone acetate.
Rationale: Transdermal estradiol avoids first-pass hepatic metabolism and is associated with a lower risk of VTE
compared to oral estrogen. Micronized progesterone has a more favorable metabolic profile than
medroxyprogesterone acetate. The levonorgestrel IUD is a progestin-only device and does not increase VTE risk;
oral estrogen alone (without progestin) would increase VTE risk. Obesity is an independent risk factor for VTE, but
transdermal route still confers lower risk. Progestogens do not reduce VTE risk; some may increase it.
Why Wrong:
B - Oral estradiol with a levonorgestrel IUD has lower VTE risk than oral conjugated equine estrogen alone
because the IUD provides local progestin without systemic effects.
C - Transdermal estrogen has lower VTE risk than oral, even in obese women.
D - Progestogens do not reduce VTE risk; some studies suggest an increased risk with certain progestins.
Reference: Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women.
Climacteric. 2020;23(sup1):S3-S8.
Page 3
, Q3. A 45-year-old woman with premature ovarian insufficiency (POI) diagnosed at age 40 has been on
transdermal estradiol 50 mcg/day with cyclic micronized progesterone 200 mg for 12 days per month. She is
now considering pregnancy. Which of the following is the most appropriate management strategy regarding
her hormone therapy?
A. Continue current hormone therapy until pregnancy is confirmed, then discontinue.
B. Switch to a continuous-combined regimen to suppress ovulation.
C. Discontinue hormone therapy and use donor oocyte in vitro fertilization (IVF) with exogenous estrogen support.
D. Increase estradiol dose to 100 mcg/day to improve endometrial receptivity.
Correct Answer: C. Discontinue hormone therapy and use donor oocyte in vitro fertilization (IVF) with exogenous
estrogen support.
Rationale: In POI, spontaneous pregnancy is rare, and most women require donor oocytes. Exogenous estrogen is needed for
endometrial preparation in IVF cycles. Current hormone therapy should be discontinued to allow controlled ovarian
stimulation or endometrial preparation. Continuous-combined therapy does not suppress ovulation sufficiently for IVF.
Increasing estradiol dose without monitoring is not recommended.
Why Wrong:
A - Hormone therapy provides only replacement levels of estrogen and does not support pregnancy; it should be replaced
by controlled IVF protocols.
B - Continuous-combined therapy is used for contraception in POI but is not appropriate for pregnancy planning.
D - Higher estrogen doses are not indicated without monitoring and may increase risks; standard IVF protocols use
monitored estrogen.
Reference: Webber L, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod.
2016;31(5):926-937.
Q4. A 58-year-old woman with a history of osteoporosis (T-score -2.8 at lumbar spine) and prior vertebral
fracture is intolerant to bisphosphonates due to severe gastrointestinal side effects. She has completed 5 years
of denosumab therapy. Which of the following is the most appropriate next step to prevent fracture?
A. Continue denosumab indefinitely without a drug holiday.
B. Transition to teriparatide for 2 years.
C. Start raloxifene therapy.
D. Administer a single dose of zoledronic acid and then observe.
Correct Answer: B. Transition to teriparatide for 2 years.
Rationale: After denosumab discontinuation, there is a high risk of rapid bone loss and rebound fractures.
Transitioning to teriparatide, an anabolic agent, can increase bone density and reduce fracture risk. Denosumab
should not be continued indefinitely beyond 5 years without reassessment, but stopping without follow-on therapy is
dangerous. Raloxifene is less potent and not first-line for severe osteoporosis with fracture. Zoledronic acid can be
used after denosumab to prevent rebound, but teriparatide provides anabolic benefit and is appropriate given prior
bisphosphonate intolerance and severe disease.
Why Wrong:
A - Denosumab beyond 5 years requires reassessment; continuing without transition increases risk of atypical
femur fractures and osteonecrosis of the jaw.
C - Raloxifene is a SERM with modest anti-fracture efficacy and is not indicated for severe osteoporosis with
prior fracture.
D - Zoledronic acid may prevent bone loss after denosumab but does not provide the anabolic effect needed
for this patient with severe osteoporosis and fracture.
Reference: Tsourdi E, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and
position statement by ECTS. Bone. 2017;105:11-17.
Page 4
